Reata Pharmaceuticals Net Income

Reata Pharmaceuticals (RETA) currently reports a net income of $-82M as of June 2023. That compares with $-300M in the prior-year period — up 73.0% year over year. That is below the Healthcare sector average of $17B. Use the charts on this page to explore Reata Pharmaceuticals's net income history and peer comparisons.

Reata Pharmaceuticals's net income increased from $-300M to $-82M — a 73.0% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Reata Pharmaceuticals's net income of $-82M is lower than the Healthcare sector average of $17B. That is roughly 100.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Reata Pharmaceuticals reported $-82M in net income as of June 2023. That compares with $-300M in the prior-year period — up 73.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-82M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $17B. From there, open related valuation or income-statement pages for Reata Pharmaceuticals, and consider following RETA for alerts when major investors trade the stock.